Corporate interest in marijuana is exploding.
As sales of beer fall in the United States, brewers have begun to bet that legalization of marijuana around the globe, especially the United States, will continue to build momentum and sales of cannabis products will take off.
For example, Constellation Brands increased its stake in Canopy Growth (CGC) by $4 billion.
That comes just 10 months after Constellation first took a 10% stake in Canopy to help create nonalcoholic cannabis-infused drinks and other products.
Molson Coors even listed legal cannabis among the biggest possible risks to its business in its annual shareholder report.
“The emergence of legal cannabis in certain U.S. states and Canada may result in a shift of discretionary income away from our products or a change in consumer preferences away from beer,” they noted.
Now, Anheuser-Busch InBev looks to be jumping on the bandwagon.
In fact, it just partnered with cannabis company, Tilray Inc. in a $100 million deal to research cannabis-infused drinks for the Canadian market. Each company will invest $50 million in the project to study non-alcoholic drinks containing CBD, or cannabidiol.
The news follows a significant amount of corporate interest in marijuana.
Just yesterday, the Canadian marijuana grower just announced a global partnership with Sandoz AG, a division of Novartis to develop and distribute medical marijuana around the globe.
That’s certainly great news for Tilray Inc.
With Novartis’ major global presence, TLRY can compete more effectively in international markets, including Australia, Germany and the United Kingdom. It also gives TLRY considerable credibility in the global cannabis industry.
All, as the medical community aggressively studies cannabis for a variety of ailments — pain, nausea, loss of appetite, Parkinson’s disease, inflammatory bowel disease, post-traumatic stress disorder, epilepsy, and multiple sclerosis and even traumatic brain injuries – the list goes on.
Even cigarette makers are jumping into the fray. Altria just took a 45% stake in Cronos Group as it seeks to diversify because of falling cigarette sales.
The multi-trillion-dollar wellness industry sees benefits, too.
With baby boomers – who make up 70% of wellness industry consumers – seeking alternatives to help improve their quality of life as they age, and younger generations more open to adding cannabis products to their health and wellness regimens, it’s only natural that the global cannabis and wellness markets would converge in a huge way.
In short, we’re just beginning to see corporate America jumping into cannabis.
We expect to see even more deals as the “fear of missing out” (FOMO) begins to hit home.
Disclaimer: We have no position in Tilray Inc. (NASDAQ: TLRY) or Canopy Growth and have not been compensated for this article.